◉ Summary of Use during Lactation:Limited data indicate that spironolactone is poorly excreted into breastmilk. Case of mothers breastfeeding during spironolactone therapy reported no adverse effects in infants. Spironolactone appears to be acceptable to use during breastfeeding.
◉ Effects in Breastfed Infants:In 17-day-old breastfed (extent not stated) infant whose mother was taking 25 mg of spironolactone 4 times daily since pregnancy, serum sodium and potassium remained normal.
Spironolactone 75 mg every other day was taken orally by a mother while nursing a newborn. She was also taking 400 mg of bretylium tosylate every 8 hours, atenolol 25 mg daily, propranolol 20 mg 3 times a day, and multivitamin, potassium and magnesium supplements. Jaundice, thought to be unrelated to the drug, occurred at 60 hours of age, but resolved. The infant had appropriate weight gain and development during the first 4 months of life.
A transgender woman took and spironolactone 50 mg twice daily to suppress testosterone, domperidone 10 mg three times daily, increasing to 20 mg four times daily, oral micronized progesterone 200 mg daily and oral estradiol to 8 mg daily and pumped her breasts 6 times daily to induce lactation. After 3 months of treatment, estradiol regimen was changed to a 0.025 mg daily patch and the progesterone dose was lowered to 100 mg daily. Two weeks later, she began exclusively breastfeeding the newborn of her partner. Breastfeeding was exclusive for 6 weeks, during which the infant's growth, development and bowel habits were normal. The patient continued to partially breastfeed the infant for at least 6 months.
A wonam with Gitleman syndrome took spironolactone in an unspecified dosage along with potassium and magnesium supplements for at least 4 months while breastfeeding her infant. No adverse infant effets were reported.
◉ Effects on Lactation and Breastmilk:Intense diuresis can suppress lactation; however, it is unlikely that spironolactone alone is sufficiently potent to cause this effect.
Spironolactone can cause gynecomastia. The estimated risk is 52 cases per 1000 patients treated, which is 8.4 times the baseline risk.
Compositions and methods for treating ocular diseases
申请人:Yee Richard W.
公开号:US10350223B2
公开(公告)日:2019-07-16
The compositions and methods disclosed herein provide for treatments of ocular disorders of the eye, such as ocular surface diseases as well as those associated with inflammation of internal cells and cell layers of the eye. The methods disclosed herein describe methods for treating ocular disorders, particularly dry eye disorders, comprising topically administering to an ocular region of a subject a composition comprising a pharmaceutically effective amount of at least one aldosterone antagonist or salt thereof and a pharmaceutically acceptable carrier. Included is a method for treating dry eye comprising topically administering to an ocular region of a subject a composition comprising spironolactone and hydroxypropyl methylcellulose; and reducing or preventing one or more symptoms or causes of dry eye.
COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
申请人:Yee Richard W.
公开号:US20180050049A1
公开(公告)日:2018-02-22
The compositions and methods disclosed herein provide for treatments of ocular disorders of the eye, such as ocular surface diseases as well as those associated with inflammation of internal cells and cell layers of the eye. The methods disclosed herein describe methods for treating ocular disorders, particularly dry eye disorders, comprising topically administering to an ocular region of a subject a composition comprising a pharmaceutically effective amount of at least one aldosterone antagonist or salt thereof and a pharmaceutically acceptable carrier. Included is a method for treating dry eye comprising topically administering to an ocular region of a subject a composition comprising spironolactone and hydroxypropyl methylcellulose; and reducing or preventing one or more symptoms or causes of dry eye.
US9849141B2
申请人:——
公开号:US9849141B2
公开(公告)日:2017-12-26
[EN] PHARMACEUTICAL COMPOSITION, COMPRISING A STEROID-DEHYDROGENASE-REDUCTASE INHIBITOR, AND A MINERALOCORTICOID RECEPTOR ANTAGONIST<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE REDUCTASE DÉSHYDROGÉNASE HYDROXYSTÉROÏDE, ET UN ANTAGONISTE DU RECEPTEUR MINERALOCORTICOÏDE
申请人:ONTOCHEM GMBH
公开号:WO2010121814A1
公开(公告)日:2010-10-28
A treatment using a hydroxysteroid dehydrogenase reductase inhibitor combined with a mineralocorticoid receptor antagonist is provided which overcomes the problem that manipulating Cortisol levels by a single compound therapy induces other pathologies or side effects, while the original condition that required treatment is ameliorated.
[EN] TREATMENT AND PREVENTION OF CANCER WITH ALDOSTERONE ANTAGONISTS<br/>[FR] TRAITEMENT ET PRÉVENTION DU CANCER AVEC DES ANTAGONISTES DE L'ALDOSTÉRONE
申请人:UNIV DUNDEE
公开号:WO2015049507A1
公开(公告)日:2015-04-09
The present invention is based on the finding that aldosterone antagonist compounds are associated with a lower incidence of cancer. Specifically, in patients prescribed aldosterone antagonists, the incidence of cancer is reduced. For example, in populations or patients undergoing long term aldosterone antagonist based treatment for chronic conditions including cardiovascular and liver disease, the incidence of cancer is lower. As such, the invention provides aldosterone antagonists for cancer treatment, prevention and/or prophylaxis.